Mobile

A Phase 2 Randomized Study of Tarceva® (erlotinib) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Newly Diagnosed Advanced Non-Small Cell Lung Cancer who have Tumors ...

Update Il y a 4 ans
Reference: EUCTR2006-005905-79

A Phase 2 Randomized Study of Tarceva® (erlotinib) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Newly Diagnosed Advanced Non-Small Cell Lung Cancer who have Tumors with EGFR Protein Overexpression and/or Increased EGFR Gene Copy Numbers

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Evaluate in parallel the efficacy of 2 different Tarceva-containing regimens as first-line therapy measured as the percentage of patients that have progressed at 6 months among stage IIIB/IV NSCLC patients selected on the basis of EGFR protein overexpression and/or increased EGFR gene copy numbers.

Inclusion criteria

  • non-small cell lung cancer

Links